Toinv – The December and March presentations both have the same slide being Slide 10 and 13 respectively. The difference is that the estimated cost of BoM2 has been reduced from $60 - $70 million to $30 - $40 million. RVX’s estimated cost has been reduced from $30 - $ 35 million to $15 - $20 million. The first line below is copied from the top of Slide 13 (March) with a similar one on Slide 10 (Dec.) with the appropriate numbers at that time. Note the ‘1’ at the end which is raised like an exponent in the presentation but copied this way. It refers you to a note ‘1’ in fine print at the bottom of these slides. I have copied it below also. It states that up to 50% of the trial is to be conducted in China and that is the portion that SH is supposed to pay.

“BETonMACE2 Estimated to cost $15-$20 million for Resverlogix1”

“1 Total clinical cost of $30-$40 million with up to 50% of the trial to be conducted in China with costs to be paid by Shenzhen Hepalink Pharmaceutical “Hepalink””